01—Abstract
Summary
Summary of the 8-K filed July 23, 2025. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher reported Q2 2025 revenue of $10.85 billiona, up 3% year over year, with organic growth of 2%.
GAAP diluted EPS rose 6% to $4.28b, helped by lower amortization of acquisition intangibles, while adjusted EPS was roughly flat at $5.36 versus $5.37. GAAP operating margin fell to 16.9% from 17.3%, and adjusted operating margin fell to 21.9% from 22.3%, so profitability slipped even as headline growth held up. Management pointed to PPI Business System cost actions and tariff-related supply chain adjustments.
The quarter's weak spot was cash generation and the Analytical Instruments segment. Free cash flow fell about 34% to $1.11 billionc from $1.67 billion, as operating cash flow dropped to $1.40 billion. Analytical Instruments revenue declined 3% to $1.73 billion, and its segment margin compressed sharply to 18.8% from 24.6%.
Life Sciences Solutions (up 6%d) and Laboratory Products and Biopharma Services (up 4%) carried growth. The filing itself contains no updated 2025 guidance. The company said it would provide revised guidance on its July 23 earnings call, so investors should weigh the filing's results against that outlook.
On the balance sheet, long-term obligations rose to $33.0 billion from $29.1 billion, and the company repurchased $2.0 billion of stock in the first half. The filing also notes a post-quarter agreement to acquire Sanofi's Ridgefield, New Jersey sterile fill-finish site.
02—Key points
Key Highlights
- Q2 revenue grew 3% to $10.85B (organic growth 2%), with acquisitions contributing nothing and currency adding about 1 point.
- GAAP diluted EPS rose 6% to $4.28, but adjusted EPS was flat at $5.36 versus $5.37, indicating the GAAP gain was mostly from lower amortization and non-core items rather than operating improvement.
- Adjusted operating margin declined to 21.9% from 22.3%, and GAAP operating margin declined to 16.9% from 17.3%.
- Free cash flow fell 34% to $1.105B from $1.674B, with operating cash flow down to $1.40B from $1.96B.
- Analytical Instruments revenue fell 3% to $1.73B and segment margin dropped to 18.8% from 24.6%, the main drag in the quarter.
- Life Sciences Solutions (+6%) and Laboratory Products and Biopharma Services (+4%) drove growth, with new instrument launches such as Orbitrap Astral Zoom and Krios 5 Cryo-TEM.
- Long-term obligations rose to $33.0B from $29.1B at year-end, while the company bought back $2.0B of stock in the first half; updated 2025 guidance was to be given on the earnings call rather than in this filing.
03—Questions
Frequently Asked Questions
Did Thermo Fisher raise or lower its 2025 guidance in this filing?
No. The 8-K states that updated 2025 financial guidance would be provided on the earnings conference call the same morning. Investors should check the call materials or any subsequent filings for the revised outlook.
Why did GAAP EPS rise while adjusted EPS was flat?
GAAP EPS benefited from a $0.14 per share year-over-year decline in amortization of acquisition-related intangibles ($1.14 versus $1.34 per share in the adjustment), while adjusted EPS excludes that amortization. Core operating profit was roughly flat, and lower margins offset the other gains.
What is driving the drop in free cash flow?
Operating cash flow fell to $1.40B from $1.96B, and the six-month reconciliation shows a $2.15B outflow from changes in assets and liabilities (versus $1.00B a year earlier). Working capital build, including higher receivables and inventories, appears to be the main factor, though the filing does not fully explain the drivers.
Is the Analytical Instruments weakness a concern?
It is the most notable operating issue in the quarter. Revenue fell 3% and segment margin dropped about 580 basis points to 18.8%, which suggests weaker demand, pricing pressure, or cost issues in that business. Investors should look for management's commentary on the call about demand and margin recovery.
What does the Sanofi site acquisition mean for investors?
The filing says Thermo Fisher expanded its partnership with Sanofi to acquire the Ridgefield, New Jersey sterile fill-finish site shortly after the quarter ended. It is positioned as expanding U.S. manufacturing capacity for pharma and biotech customers. The filing does not disclose the purchase price or financial impact.
04—Continue